Active Ingredient(s): Capmatinib Hydrochloride
FDA Approved: * May 6, 2020
Pharm Company: * NOVARTIS PHARM
Category: Cancer

Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR, as detected by an FDA-approved test.[1][2][3] The most common adverse reactions are peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.[1]&... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tabrecta 150 mg Oral Tablet, Film Coated
NDC: 0078-0709
Novartis Pharmaceuticals Corporation
Tabrecta 200 mg Oral Tablet, Film Coated
NDC: 0078-0716
Novartis Pharmaceuticals Corporation